Search

everythinglearnresearchcommunity

for

Search:↓

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Switching to generic tacrolimus was safe, effective, and saved money.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Flutamide rarely causes liver toxicity in prostate cancer patients.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.